Indivior obtains court order to block generic Suboxone
Addiction treatment drug producer Indivior has obtained a temporary restraining order against Indian generic maker Dr Reddy’s, blocking the company from launching a generic version of Suboxone (buprenorphine and naloxone) Film.
On Friday, June 15, UK-based Indivior announced that the US District Court for the District of New Jersey granted the temporary restraining order.
The order will remain in place pending a hearing on a preliminary injunction motion filed by Indivior the same day.
Indivior is seeking to stop the launch of Dr Reddy’s generic, pending the outcome of litigation against the Indian generic maker relating to US patent number 9,931,305.
A hearing on the motion has been scheduled for June 28.
Shaun Thaxter, CEO of Indivior, said: “This order will stop Dr Reddy’s launch activities before the court has had a chance to rule on the preliminary injunction motion. We will continue to pursue all legal avenues against Dr Reddy’s to protect our Suboxone Film patent estate.”
In response to the motion, Dr Reddy’s said that it remains confident in its legal positions on this patent and “believes it will prevail on the issues raised with respect to the application for injunction”.
According to the India-based company, the restraining order stops it from further sales and commercialisation of the generic within the US, but does not include a prohibition on commercial manufacturing of the product.
One day before Indivior’s announcement, Mylan Technologies and Dr. Reddy's received approval from the US Food and Drug Administration for the first generic versions of Suboxone Film.
Did you enjoy reading this story? Sign up to our free daily newsletters and get stories sent like this straight to your inbox.
